|
|
|
 |
FDA Approval Activities for this Drug…
Adenoscan (Adenosine) Injection, Fujisawa Healthcare, NDA 20-059/S7 8/31/01 11/5/01 11/5/01 11/7/01 Adenoscan Indications: Adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. | Adenosine Injection, 3 mg/mL, Sicor ANDA 76-564 9/23/03 | Adenosine Injection, 3 mg/mL, Baxter Healthcare ANDA 76-500 5/14/03 | Adenosine Injection, 3 mg/mL, Baxter Healthcare ANDA 76-501 5/14/03 | Adenosine Injection, 3 mg/mL, 2 mL & 4 mL, Bedford ANDA 76-404 | | Adenosine Injection, American Pharma, Approval | Adenocard (adenosine) Injection, Astellas Pharma, Labeling Revision | Adenoscan (adenosine) Injection, Astellas Pharma, Labeling Revision | Adenosine Injection, Sicor Pharma, Tentative Approval | Adenosine Injection, Abraxis Pharma, Tentative Approval | Adenosine Injection, Gland Pharma, Approval | Adenosine Injection, Bedford Laboratories, Tentative Approval | Adenosine Injection, Akorn Inc., Approval | Adenosine Injection, Wockhardt, Ltd., Tentative Approval | Adenosine Injection, Luitpold Pharmaceuticals, Inc., Approval | Adenosine Injection, Strides Arcolab Ltd., Approval | Adenosine Injection, Wockhardt, Ltd., Approval | Adenocard (adenosine) Injection, Astellas Pharma US, Inc., Labeling Revision | Adenosine Injection, Akorn Inc., Tentative Approval | Adenosine Injection, Sagent Strides LLC, Tentative Approval | Adenocard (adenosine) Injection, Astellas Pharma, Inc., Labeling Revision
  
|